Lupin Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

A US District Court's rejection of generic firms' arguments regarding the Astellas patent is a setback for Lupin and Zydus, affecting their Myrbetriq sales potential.

US Court Ruling Impacts Lupin's Generic Myrbetriq Sales - 13 Jun, 2025

Lupin Limited has received tentative approval from the USFDA for its Oxcarbazepine Extended-Release Tablets, indicating a significant market opportunity with annual US sales of approximately $206 million.

Lupin Secures FDA Approval for Generic Drug - 07 Jun, 2025

Lupin Ltd shares rose after a US Court permitted the expansion of patent arguments regarding Mirabegron, enhancing their defense for an at-risk launch and reducing penalty risks. Axis Capital issued a positive note, maintaining a Buy rating on Lupin with a target price of Rs 2,500.

Lupin Gains from Expanded Patent Argument Scope - 05 Jun, 2025

Lupin Ltd has converted a loan to equity for its oncology unit, announced a partnership for biosimilar Ranibizumab in Latin America, and will present oncology trial data at ASCO 2025.

Lupin Announces Key Partnerships and Clinical Data Presentation - 26 May, 2025

ICICI Securities maintains a HOLD rating on Lupin with a target price of Rs 2,110. The company's Q4FY25 performance was driven by strong sales in Mirabegron and gPred Forte, despite upcoming challenges. While India business growth has slowed, management anticipates recovery in FY26. EPS estimates for FY26/27 have been slightly raised, but overall revenue growth is expected to be moderate.

ICICI Securities Maintains HOLD on Lupin with Target Price - 21 May, 2025

Lupin Ltd announced its partnership with Honeywell to utilize Solstice Air propellant in next-generation inhalers, targeting asthma and COPD patients while significantly reducing greenhouse gas emissions.

Lupin Partners with Honeywell for Eco-Friendly Inhalers - 20 May, 2025

Lupin aims to enhance its specialty business by increasing revenue from complex generics in the US and EU. With over 200 products planned for launch, the company expects complex generics to contribute 62% to overall revenues by FY30, up from 21% in FY26.

Lupin Targets Growth in Complex Generics Market - 19 May, 2025

Lupin aims to launch over 80 products in India and 50 in developed markets in five years. Brokerages maintain 'Buy' ratings, citing strong growth potential in complex generics and margin expansion.

Lupin Plans Major Product Launches and Growth - 16 May, 2025

Lupin Ltd reported a significant increase in Q4 net profit and sales, while also receiving FDA approval for Rivaroxaban Tablets, indicating strong growth potential. Executives highlighted US revenue stabilization and ongoing challenges in the market.

Lupin Reports Strong Earnings and FDA Approval - 15 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 3 years, LUPIN stock has moved up by 228.2%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 16.92% to 17.55% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 20.6%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

Netprofit is down for the last 2 quarters, 855.16 Cr → 772.52 Cr (in ₹), with an average decrease of 9.7% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Revenue is down for the last 2 quarters, 5.82K Cr → 5.72K Cr (in ₹), with an average decrease of 1.7% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Promoters have decreased holdings from 46.95% to 46.92% in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Down

Foreign Institutions have decreased holdings from 22.04% to 21.46% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Retail Investor have decreased holdings from 6.26% to 6.20% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

NIFTY PHARMA

BSE 100

S&P BSE 250 LargeMidCap

Nifty Midcap 100

BSE Mid-Cap

BSE 200

Nifty Midcap Sel

S&P BSE Momentum

Nifty Midcap 50

Nifty Midcap 150

Nifty 200

Nifty LargeMidcap 250

S&P BSE 100 ESG

Nifty 500

Nifty Alpha 50

S&P BSE SEN. N50

Nifty Midcap Liquid 15

Nifty Healthcare

Nifty MidSmallcap 400

S&P BSE 150 MidCap

S&P BSE MidCap Select

S&P BSE 400 MidSmallCap

BSE Healthcare

BSE 500

HDFC Balanced Advantage Fund Direct Plan Growth Option

HDFC Large Cap Fund -Direct Plan - Growth Option

Mirae Asset Large & Midcap Fund Direct Plan Growth

ICICI Prudential Value Discovery Fund Direct Plan Growth

Axis Midcap Fund Direct Plan Growth

Lupin Ltd’s net profit jumped 114.93% since last year same period to ₹772.52Cr in the Q4 2024-2025. On a quarterly growth basis, Lupin Ltd has generated -9.66% fall in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-0.09	Bullish
CCI (20)	62.64	Neutral
RSI (14)	57.76	Neutral
Momentum (10)	3.1	Bearish
ADI (14)	46.76	Bullish
Ultimate Oscillator (7,14,28)	60.36	Neutral

Name	Value	Action
SMA (20)	1999.75	Bullish
EMA (20)	2000.12	Bullish
VWMA (20)	1999.75	Bullish
SMA (50)	2000.94	Bullish
EMA (50)	2000.71	Bullish
SMA (200)	1999.92	Bullish
EMA (200)	2001.85	Bullish
KAMA (200)	2000.64	Bullish
DEMA (200)	1998.77	Bullish

Lupin Ltd (LUPIN)

Summary

Overall

Oscillators

Moving Averages